Claims
- 1. A compound of the formula
- 2. A compound of the formula
- 3. A pharmaceutical composition comprising a compound of the formula
- 4. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for oral administration.
- 5. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for topical administration.
- 6. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.
- 7. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous administration.
- 8. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intraperitoneal administration.
- 9. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intramuscular administration.
- 10. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for submucosal administration.
- 11. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for inhalation administration.
- 12. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for transdermal administration.
- 13. A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- 14. The method of claim 13, wherein the inflammatory disorder is arthritis.
- 15. The method of claim 13, wherein the inflammatory disorder is rheumatoid arthritis.
- 16. The method of claim 13, wherein the inflammatory disorder is osteoarthritis.
- 17. The method of claim 13, wherein the inflammatory disorder is asthma.
- 18. The method of claim 13, wherein the inflammatory disorder is dermatitis.
- 19. The method of claim 13, wherein the inflammatory disorder is multiple sclerosis.
- 20. The method of claim 13, wherein the inflammatory disorder is psoriasis.
- 21. A method for the treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- 22. A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- 23. The method of claim 22, wherein the cardiovascular disorder is selected from the group consisting of atherosclerosis, post-angioplasty restenosis, coronary artery disease, angina and small artery disease.
- 24. A method for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
- 25. The method of claim 24, wherein the redox-sensitive gene expresses cytokines.
- 26. A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula
Parent Case Info
[0001] This application claims priority to U.S. provisional application serial No. 60/047,020 filed on May 14, 1997.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60047020 |
May 1997 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09370046 |
Aug 1999 |
US |
Child |
10114346 |
Apr 2002 |
US |
Parent |
09079213 |
May 1998 |
US |
Child |
09370046 |
Aug 1999 |
US |